Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Karos Pharmaceuticals
New Haven, Connecticut, United Stateskarospharma.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
Karos Pharmaceuticals was a privately held, clinical-stage biopharmaceutical company focused on developing small molecule therapeutics that modulate peripheral serotonin synthesis via TPH1 inhibition. Its lead program advanced to Phase 2 clinical trials targeting pulmonary arterial hypertension. The company also explored treatments for carcinoid syndrome and various fibrotic, inflammatory, and metabolic rare diseases. Karos was acquired in August of 2017.
- Therapeutic areas
- CardiovascularMetabolic DisordersImmunologyOncologyRare Diseases
- Modalities
- Small molecules (notably TPH1 inhibitors)
- Industry
- Biotech
Beyond the preview
Go deeper on Karos Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Karos Pharmaceuticals.